Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Biopsy 8fludarabine phosphate 7Whole-Body Irradiation 6Tacrolimus 5Mycophenolic Acid 5Epoetin Alfa 5Colposcopy 5Celecoxib 5Busulfan 5Aminolevulinic Acid 5Sulindac 4Selenium 4Methotrexate 4Melphalan 4Cyclosporine 4Cetuximab 4Antilymphocyte Serum 4Polymerase Chain Reaction 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Gene Expression Profiling 3Etoposide 3Eflornithine 3Darbepoetin alfa 3Carboplatin 3Aspirin 3fludarabine 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Precancerous Conditions × alethine × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡